An FDA advisory committee has recommended against approval of Reata Pharmaceuticals' bardoxolone. The drug is being developed to treat patients with chronic kidney disease caused by Alport syndrome. The committee felt that the evidence presented did not show a slowing of progression of CKD in patients with Alport syndrome. The final decision rests with the FDA, which is not required to follow the committee's vote.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept